0001493152-21-004102.txt : 20210217 0001493152-21-004102.hdr.sgml : 20210217 20210217061505 ACCESSION NUMBER: 0001493152-21-004102 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20210217 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210217 DATE AS OF CHANGE: 20210217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USA EQUITIES CORP. CENTRAL INDEX KEY: 0000856984 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 112655906 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19041 FILM NUMBER: 21642570 BUSINESS ADDRESS: STREET 1: 901 NORTHPOINT PARKWAY STREET 2: SUITE 302 CITY: WEST PALM BEACH STATE: FL ZIP: 33407 BUSINESS PHONE: (929) 379-6503 MAIL ADDRESS: STREET 1: 901 NORTHPOINT PARKWAY STREET 2: SUITE 302 CITY: WEST PALM BEACH STATE: FL ZIP: 33407 FORMER COMPANY: FORMER CONFORMED NAME: USA EQUITY CORP. DATE OF NAME CHANGE: 20151116 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN BIOGENETIC SCIENCES INC DATE OF NAME CHANGE: 19940426 8-K 1 form8-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): February 17, 2021

 

USA EQUITIES CORP.

(Exact Name of Registrant as Specified in its Charter)

 

0-19041

(Commission File No.)

 

Delaware   30-1104301
(State of Incorporation)   (I.R.S. Employer Identification No.)

 

901 Northpoint Parkway Suite 302 West Palm Beach FL 33407   33407
(Address of Principal Executive Offices)   (ZIP Code)

 

Registrant’s telephone number, including area code: (929) 379-6503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   USAQ   OTCMKTS

 

 

 

   

 

 

Item 7.01 Regulation FD Disclosure.

 

On February 17, 2021, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp (USAQ) Announces Newest Advisory Board Members in First Quarter 2021”.

 

A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.

 

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/mpi_usaq), its LinkedIn account (https://www.linkedin.com/company/medicalpracticeincome/) its Facebook account (https://www.facebook.com/medicalpracticeincome), as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

 

ITEM 9.01 Financial Statements and Exhibits

 

Exhibit No.   Description
     
99.1   Press release dated February 17, 2021 entitled “USA Equities Corp (USAQ) Announces Newest Advisory Board Members in First Quarter 2021

 

The press release may contain hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: February 17, 2021  
     
USA Equities Corp.  
     
  /s/: Troy Grogan  
Name: Troy Grogan  
Title: CEO and Chairman  

 

   

 

 

EX-99.1 2 ex99-1.htm

 

 

EXHIBIT 99.1

 

 

USA Equities Corp (USAQ) Announces Newest Advisory Board Members in First Quarter 2021

 

WEST PALM BEACH, FL – (February 17, 2021) – USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) is focused on enabling primary care physicians (PCP’s) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease through reimbursable procedures. The Company announced today its newest appointments to the medical and scientific advisory board. Joining the team of leading researchers and medical experts is Björn Herman, MD, FACS, who serves as the Assistant Professor of Otolaryngology at the University of Miami Miller School of Medicine; Frank Lichtenberger, MD, Ph.D., Board Certified Internist, and Allergy Immunologist; Juan Escobar, MD. Internal Medicine; and Fredric W. Pullen, II MD, FACS, Professor, vol., Otolaryngology, at the University of Miami, Miller School of Medicine.

 

“We are very proud that three of our new Medical Advisory Board members are also current clients” states Troy Grogan, President, and CEO at USA Equities Corp.

 

USAQ is led by a group of concerned doctors, academics, health professionals, informatics, and information technology professionals, with a shared goal of seeing individuals take control of their health through physician-directed digital medicine and innovative, AI-enhanced, preventive health technologies that streamline the care process. We are a medical device technology company focused on enabling primary care physicians (PCP’s) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease through reimbursable point of care and SaaS procedures.

 

Our first addition is Björn Herman, MD, FACS, who serves as the Assistant Professor of Otolaryngology at the University of Miami Miller School of Medicine. Dr. Herman graduated from Yale University before receiving his M.D. from Columbia University College of Physicians and Surgeons. He then completed his Otolaryngology residency at Jackson Memorial Hospital and the University of Miami. After residency, Dr. Herman spent three years in Ohio. He worked for Holzer Health System and was an Adjunct Assistant Professor in the Department of Otolaryngology at the Ohio State University. He returned to the University of Miami as a general otolaryngologist with a special interest in endoscopic sinus surgery in 2015, helping develop the university’s satellite clinics in Palm Beach County, and developing the Department of Otolaryngology’s allergy program. Dr. Herman has published many journals articles throughout his career, including publications in Otolaryngology-Head and Neck Surgery, the International Journal of Pediatric Otorhinolaryngology, the Annals of Otology, Rhinology, and Laryngology, the Journal of the Society of Endoscopic and Laparoscopic Surgeons, the American Journal of Surgery, and the World Journal of Surgery.

 

   

 

 

Next, we’re proud to announce the addition of Frank Lichtenberger, MD, Ph.D., Board Certified Internist, and Allergy Immunologist. Dr. Lichtenberger has been practicing in North Carolina since he finished his Fellowship training at the National Institutes of Health. He is recognized by his peers and industry as an expert and thought leader in the conditions of Primary Immunodeficiency, Hereditary Angioedema, and Mast Cell Disorders. He has an independent grant to study mast cell-related inflammation markers and is active in internationally sponsored clinical trials. His wife and two young children keep him busy, but he stays active with his indoor hydroponic gardening hobbies. Industry and oversight monitoring show that he is ranked #1 in North Carolina amongst Allergy/Immunology practitioners for care complexity.

 

Juan Escobar, MD. is an avid user of the Company’s allergy testing and treatment products, he is an internal medicine specialist who practices in Florida’s Treasure Coast area. Dr. Escobar completed his residency and training at the North Shore Medical Center, located on the North Shore of Boston, MA - the second largest community hospital system in Massachusetts. Dr. Escobar has more than 25 years practicing internal medicine in a clinical setting and is interested in anti-aging medicine. Dr. Escobar is a member of the American Academy of Anti-Aging Medicine, where he completed a fellowship in anti-aging medicine and nutrition. “I am constantly looking for innovation and ‘what’s next’ in healthcare and that’s why I’m joining Troy Grogan and his team at USAQ,” said Dr. Escobar. He also served as a Medical Director at NeuroTechnology, which worked with individuals, assisting the development of optimal brain states, a technology used to help Olympic athletes, celebrities, and individuals who want to improve memory, capacity for achievement, and a more balanced lifestyle. He believes strongly in innovation within medical practices and equipping physicians with the additional tools to transform their practices.

 

Finally, we’re proud to announce the addition of Fredric W. Pullen, II MD, FACS, Professor, vol., Otolaryngology, at the University of Miami, Miller School of Medicine. Dr. Pullen studied bacteriology at the University of Michigan and received his Doctor of Medicine at the University of Michigan Medical School, where he published his first of many peer-reviewed scientific articles and several books. He continued his studies at Harvard Medical School and the Massachusetts Eye and Ear Infirmary/Massachusetts General Hospital in Boston, in Otorhinolaryngology. Dr. Pullen served in the United States Air Force as an ear, nose, and throat specialist and vice commander of the 7272 USAF Hospital, obtaining the Major’s rank. After his service, he returned to academic medicine at the University of Miami, becoming a clinical professor in the Otolaryngology department and a consultant to the Air Force Surgeon General. He began treatment of allergic disease using skin testing and oral and subcutaneous immunotherapy in his private practice. Dr. Pullen was a founder of Interactive Telemedicine Systems, The Hearing, Education and Research Foundation (HEAR), American Educational Designers (First use of Videotape teaching in medicine), Chief editor of Video-digest, The National Hearing Conservation Association, and Allertemp, providing allergy services to physicians offices throughout south Florida. Dr. Pullen is currently a Fellow with several leading medical organizations: American College of Surgeons, American Academy of Facial Plastic and Reconstructive Surgery (emeritus), American Academy of Otolaryngology-Head and Neck Surgery, American Laryngological, Rhinological and Otological Society, American Neurotology Society, Past President He is a member of other prestigious and respected medical organizations, including the American Academy of Otolaryngic Allergy, and the American Medical Association. Dr. Pullen is also a recipient of the Honor Award from the American Academy of Otolaryngology.

 

About USA Equities Corp (OTCQB: USAQ)

 

On December 20, 2019 USA Equities Corp completed a share exchange whereby it acquired Medical Practice Income, Inc. (MPI). The Company is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population. The Company is located in West Palm Beach, Florida. For more information, visit www.USAQCorp.com

 

   

 

 

Forward-Looking Statements

 

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

 

 

 

Investor & Media Contact:  
Olivia Giamanco  
USA Equities Corp  
(929) 379-6503  
IR@USAQCORP.COM  

 

 

 

   

 

 

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end